Literature DB >> 8027371

p53 expression in anaplastic carcinomas arising from thyroid papillary carcinomas.

X Matias-Guiu1, M Cuatrecasas, E Musulen, J Prat.   

Abstract

AIM: To study the expression of p53 tumour suppressor gene in anaplastic carcinomas arising from thyroid papillary carcinomas.
METHODS: Formalin fixed, paraffin wax embedded tissues from four cases of anaplastic carcinomas associated with thyroid papillary carcinomas were studied by immunohistochemistry with two different p53 monoclonal antibodies.
RESULTS: The anaplastic component showed nuclear immunostaining in two cases, but not in the other two. In all cases the papillary carcinoma component was negative.
CONCLUSION: The results support the hypothesis that p53 stimulates tumour progression in thyroid tumours.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8027371      PMCID： PMC501937          DOI： 10.1136/jcp.47.4.337

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


  10 in total

1.  P53 in tumour pathology: can we trust immunocytochemistry?

Authors:  D Wynford-Thomas
Journal:  J Pathol       Date:  1992-04       Impact factor: 7.996

2.  The p53 proto-oncogene can act as a suppressor of transformation.

Authors:  C A Finlay; P W Hinds; A J Levine
Journal:  Cell       Date:  1989-06-30       Impact factor: 41.582

3.  Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.

Authors:  J Bartek; R Iggo; J Gannon; D P Lane
Journal:  Oncogene       Date:  1990-06       Impact factor: 9.867

4.  Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma.

Authors:  Y Dobashi; A Sakamoto; H Sugimura; M Mernyei; M Mori; T Oyama; R Machinami
Journal:  Am J Surg Pathol       Date:  1993-04       Impact factor: 6.394

5.  Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.

Authors:  R Donghi; A Longoni; S Pilotti; P Michieli; G Della Porta; M A Pierotti
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

6.  The cellular protein p53 in human tumours.

Authors:  L V Crawford; D C Pim; P Lamb
Journal:  Mol Biol Med       Date:  1984-08

7.  Undifferentiated and poorly differentiated carcinoma.

Authors:  J Rosai; E A Saxén; L Woolner
Journal:  Semin Diagn Pathol       Date:  1985-05       Impact factor: 3.464

8.  Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland.

Authors:  T Ito; T Seyama; T Mizuno; N Tsuyama; T Hayashi; Y Hayashi; K Dohi; N Nakamura; M Akiyama
Journal:  Cancer Res       Date:  1992-03-01       Impact factor: 12.701

9.  High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.

Authors:  J A Fagin; K Matsuo; A Karmakar; D L Chen; S H Tang; H P Koeffler
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

10.  p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas.

Authors:  T Nakamura; I Yana; T Kobayashi; E Shin; K Karakawa; S Fujita; A Miya; T Mori; I Nishisho; S Takai
Journal:  Jpn J Cancer Res       Date:  1992-12
  10 in total
  9 in total

1.  Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas.

Authors:  K M La Perle; S M Jhiang; C C Capen
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  Possible Relation of p53 and mdm-2 Oncoprotein Expression in Thyroid Carcinoma: A Molecular-Pathological and Immunohistochemical Study on Paraffin-Embedded Tissue.

Authors:  Kurt W. Schmid; Agnes Bankfalvi; Swantja Mucke; Dietmar Ofner; Kristina Riehemann; Soren Schroder; Andrea Stucker; Martin Totsch; Barbara Dockhorn-Dworniczak
Journal:  Endocr Pathol       Date:  1996       Impact factor: 3.943

3.  Cell growth and p53 expression in primary acquired melanosis and conjunctival melanoma.

Authors:  S Seregard
Journal:  J Clin Pathol       Date:  1996-04       Impact factor: 3.411

4.  Coexisting well-differentiated and anaplastic thyroid carcinoma in the same primary resection specimen: immunophenotypic and genetic comparison of the two components in a consecutive series of 13 cases and a review of the literature.

Authors:  Moira Ragazzi; Federica Torricelli; Benedetta Donati; Alessia Ciarrocchi; Dario de Biase; Giovanni Tallini; Eleonora Zanetti; Alessandra Bisagni; Elisabetta Kuhn; Davide Giordano; Andrea Frasoldati; Simonetta Piana
Journal:  Virchows Arch       Date:  2020-07-18       Impact factor: 4.064

5.  Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21.

Authors:  K Y Lam; C Y Lo; K W Chan; K Y Wan
Journal:  Ann Surg       Date:  2000-03       Impact factor: 12.969

6.  K-ras and p53 mutations in hamster pancreatic ductal adenocarcinomas and cell lines.

Authors:  N Erill; M Cuatrecasas; F J Sancho; A Farré; P M Pour; F Lluís; G Capellá
Journal:  Am J Pathol       Date:  1996-10       Impact factor: 4.307

Review 7.  Genetics and epigenetics of sporadic thyroid cancer.

Authors:  Dang Vu-Phan; Ronald J Koenig
Journal:  Mol Cell Endocrinol       Date:  2013-08-08       Impact factor: 4.102

8.  Papillary microcarcinomas of the thyroid gland and immunohistochemical analysis of expression of p53 protein in papillary microcarcinomas.

Authors:  Demet Corapcioglu; Serpil D Sak; Tuncay Delibasi; Vedia Tonyukuk; Nuri Kamel; Ali R Uysal; Savas Kocak; Semih Aydintug; Gurbuz Erdogan
Journal:  J Transl Med       Date:  2006-07-05       Impact factor: 5.531

9.  UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas.

Authors:  P Pallante; M T Berlingieri; G Troncone; M Kruhoffer; T F Orntoft; G Viglietto; A Caleo; I Migliaccio; M Decaussin-Petrucci; M Santoro; L Palombini; A Fusco
Journal:  Br J Cancer       Date:  2005-08-22       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.